Ph 2 LUNAR-4 trial of TTFs + Keytruda in metastatic NSCLC patients terminated
“The company notified trial sites of the termination on August 28, 2025. LUNAR-4 was a phase 2, single arm, open-label, multinational study examining Tumor Treating Fields used alongside pembrolizumab for treating metastatic non-small cell lung cancer in patients previously treated with a PD-1/PD-L1 inhibitor and platinum-based chemotherapy. The company stated that the availability of real-world evidence will allow it to achieve the objectives of LUNAR-4 without conducting an interventional clinical study. Novocure emphasized that the decision was not related to any safety concerns.”
Share:
More News
“Initiation of the TEADCO Phase 1b/2 basket trial is another important milestone for the ODM-212 clinical development program and reflects our commitment to patients with difficult-to-treat cancers,” said Professor Outi Vaarala, Executive Vice President, Research & Development at Orion. “Together with the ongoing TEADES study, TEADCO highlights the versatility of
“In this study, tovecimig showed an impressive overall response rate which translated into a clinically meaningful and highly statistically significant improvement in PFS for patients with previously treated BTC. The remarkable 56% reduction in the risk of disease progression is unprecedented in this patient population without an actionable mutation in
“We are encouraged to see taletrectinib (IBTROZI) added to the NCCN Guidelines® for CNS Cancers given its demonstrated high rates of intracranial response that are durable in ROS1+ NSCLC patients with brain metastases,” said David Hung, M.D., Founder, President and Chief Executive Officer of Nuvation Bio. “Given the prevalence of
Daniel Getts, Ph.D., CEO of CREATE, added “MT-304 is proof of what our platform can do, and what our team can execute. Our mRNA-LNP leadership enables us to move from concept to clinic with remarkable speed. Just last weekend at AACR, we presented compelling preclinical data across our in vivo